Sodium tungstate modulates ATM function upon DNA damage

FEBS Letters

Volumn 587, Issue 10, 2013, Pages 1579-1586

  Rodriguez Hernandez, C J ^a,g   Llorens Agost, M ^b,c   Calbo J ^a   Murguia, J R ^b,f   Guinovart, J J ^a,d,e  

^a INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^b Universitat Politècnica de València   (Spain)

^c NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^d UNIVERSITY OF BARCELONA   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

^f BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^g HOSPITAL SANT JOAN DE DÉU   (Spain)

Author keywords

Antitumoral; DNA damage; Double strand break; Phosphatase inhibition

Indexed keywords

ATM PROTEIN; ETOPOSIDE; MRE11 PROTEIN; NIBRIN; PHLEOMYCIN; PP2A PROTEIN; RAD50 PROTEIN; TUNGSTATE SODIUM; TUNGSTEN DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DNA DAMAGE; DNA STRAND BREAKAGE; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IONIZING RADIATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; CELL CYCLE PROTEINS; CELL PROLIFERATION; CELLS, CULTURED; DNA BREAKS, DOUBLE-STRANDED; DNA DAMAGE; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HEK293 CELLS; HELA CELLS; HUMANS; MICE; PROTEIN-SERINE-THREONINE KINASES; RADIATION DOSAGE; RADIATION, IONIZING; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS; TUNGSTEN COMPOUNDS;

EID: 84877751798     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2013.04.003     Document Type: Article

References (49)

1. Hait, W. N. (2010) Anticancer drug development: the grand challenges. Nat. Rev. Drug Discov. 9, 253-254.
2. S. Marchetti, and J.H. Schellens The impact of FDA and EMEA guidelines on drug development in relation to phase 0 trials Br. J. Cancer 97 2007 577 581
3. J.H. Lee, and T.T. Paull Activation and regulation of ATM kinase activity in response to DNA double-strand breaks Oncogene 26 2007 7741 7748
4. Abdel-Razeq, H. and Marei, L. (2011) Current neoadjuvant treatment options for HER2-positive breast cancer. Biologics 5, 87-94.
5. Chiang, C.L., Kandalaft, L.E. and Coukos, G. (2011) Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines. Int. Rev. Immunol. 30, 150-182.
6. Farooque, A., Mathur, R., Verma, A., Kaul, V., Bhatt, A.N., et al. (2011) Low-dose radiation therapy of cancer: role of immune enhancement. Expert Rev. Anticancer Ther. 11, 791-802.
7. Martinez Guisado, A., Sanchez Munoz, A., de la Cabeza Lomas Garrido, M., Ruiz Borrego, M., Bayo Calero, J., et al. (2011) Initialization of adjuvant hormonal treatment for breast cancer. Adv. Ther. 28, Suppl. 6, 66-84.
8. J.L. Domingo Vanadium and tungsten derivatives as antidiabetic agents: a review of their toxic effects Biol. Trace Elem. Res. 88 2002 97 112
9. A. Barbera, R.R. Gomis, N. Prats, J.E. Rodriguez-Gil, and M. Domingo Tungstate is an effective antidiabetic agent in streptozotocin-induced diabetic rats: a long-term study Diabetologia 44 2001 507 513
10. A. Barbera, J. Fernandez-Alvarez, A. Truc, R. Gomis, and J.J. Guinovart Effects of tungstate in neonatally streptozotocin-induced diabetic rats: mechanism leading to normalization of glycaemia Diabetologia 40 1997 143 149
11. A. Barbera, J.E. Rodriguez-Gil, and J.J. Guinovart Insulin-like actions of tungstate in diabetic rats. Normalization of hepatic glucose metabolism J. Biol. Chem. 269 1994 20047 20053
12. M.C. Munoz, A. Barbera, J. Dominguez, J. Fernandez-Alvarez, and R. Gomis Effects of tungstate, a new potential oral antidiabetic agent, in Zucker diabetic fatty rats Diabetes 50 2001 131 138
13. M. Claret, H. Corominola, I. Canals, J. Saura, and S. Barcelo-Batllori Tungstate decreases weight gain and adiposity in obese rats through increased thermogenesis and lipid oxidation Endocrinology 146 2005 4362 4369
14. M.P. Egloff, P.T. Cohen, P. Reinemer, and D. Barford Crystal structure of the catalytic subunit of human protein phosphatase 1 and its complex with tungstate J. Mol. Biol. 254 1995 942 959
15. E.B. Fauman, C. Yuvaniyama, H.L. Schubert, J.A. Stuckey, and M.A. Saper The X-ray crystal structures of Yersinia tyrosine phosphatase with bound tungstate and nitrate. Mechanistic implications J. Biol. Chem. 271 1996 18780 18788
16. J.D. Foster, S.E. Young, T.D. Brandt, and R.C. Nordlie Tungstate: a potent inhibitor of multifunctional glucose-6-phosphatase Arch. Biochem. Biophys. 354 1998 125 132
17. J.A. Stuckey, H.L. Schubert, E.B. Fauman, Z.Y. Zhang, and J.E. Dixon Crystal structure of Yersinia protein tyrosine phosphatase at 2.5 Å and the complex with tungstate Nature 370 1994 571 575
18. Rodriguez-Hernandez, C.J., Guinovart, J.J. and Murguia, J.R. (2012) Anti-diabetic and anti-obesity agent sodium tungstate enhances GCN pathway activation through Glc7p inhibition. FEBS Lett. 586, 270-276.
19. Hanzu, F., Gomis, R., Coves, M.J., Viaplana, J., Palomo, M., et al. (2010) Proof-of-concept trial on the efficacy of sodium tungstate in human obesity. Diabetes Obes. Metab. 12, 1013-1018.
20. W. Prinz Guide to Yeast Genetics and Molecular Cell Biology C. Guthrie, G.R. Fink, Guide to Yeast Genetics and Molecular Cell Biology, Part B Methods in Enzymology vol. 350 2003 Academic Press New York
21. J.W. Theunissen, M.I. Kaplan, P.A. Hunt, B.R. Williams, and D.O. Ferguson Checkpoint failure and chromosomal instability without lymphomagenesis in Mre11(ATLD1/ATLD1) mice Mol. Cell. 12 2003 1511 1523
22. T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J. Immunol. Methods 65 1983 55 63
23. B.R. Williams, O.K. Mirzoeva, W.F. Morgan, J. Lin, and W. Dunnick A murine model of Nijmegen breakage syndrome Curr. Biol. 12 2002 648 653
24. S.R. Silberman, M. Speth, R. Nemani, M.K. Ganapathi, and V. Dombradi Isolation and characterization of rabbit skeletal muscle protein phosphatases C-I and C-II J. Biol. Chem. 259 1984 2913 2922
25. S.P. Jackson Sensing and repairing DNA double-strand breaks Carcinogenesis 23 2002 687 696
26. P. Heisig Type II topoisomerases-inhibitors, repair mechanisms and mutations Mutagenesis 24 2009 465 469
27. D. Nakada, Y. Hirano, and K. Sugimoto Requirement of the Mre11 complex and exonuclease 1 for activation of the Mec1 signaling pathway Mol. Cell. Biol. 24 2004 10016 10025
28. M.F. Lavin, and S. Kozlov ATM activation and DNA damage response Cell Cycle 6 2007 931 942
29. R. Kitagawa, C.J. Bakkenist, P.J. McKinnon, and M.B. Kastan Phosphorylation of SMC1 is a critical downstream event in the ATM-NBS1-BRCA1 pathway Genes Dev. 18 2004 1423 1438
30. L.C. Riches, A.M. Lynch, and N.J. Gooderham Early events in the mammalian response to DNA double-strand breaks Mutagenesis 23 2008 331 339
31. A. Ali, J. Zhang, S. Bao, I. Liu, and D. Otterness Requirement of protein phosphatase 5 in DNA-damage-induced ATM activation Genes Dev. 18 2004 249 254
32. A.A. Goodarzi, J.C. Jonnalagadda, P. Douglas, D. Young, and R. Ye Autophosphorylation of ataxia-telangiectasia mutated is regulated by protein phosphatase 2A EMBO J. 23 2004 4451 4461
33. T.A. Haystead, A.T. Sim, D. Carling, R.C. Honnor, and Y. Tsukitani Effects of the tumour promoter okadaic acid on intracellular protein phosphorylation and metabolism Nature 337 1989 78 81
34. J.H. Petrini, and T.H. Stracker The cellular response to DNA double-strand breaks: defining the sensors and mediators Trends Cell Biol. 13 2003 458 462
35. M. Grenon, C. Gilbert, and N.F. Lowndes Checkpoint activation in response to double-strand breaks requires the Mre11/Rad50/Xrs2 complex Nat. Cell Biol. 3 2001 844 847
36. T.T. Paull, and M. Gellert A mechanistic basis for Mre11-directed DNA joining at microhomologies Proc. Natl. Acad. Sci. USA 97 2000 6409 6414
37. Y. Wu, S. Xiao, and X.D. Zhu MRE11-RAD50-NBS1 and ATM function as co-mediators of TRF1 in telomere length control Nat. Struct. Mol. Biol. 14 2007 832 840
38. O.K. Mirzoeva, and J.H. Petrini DNA damage-dependent nuclear dynamics of the Mre11 complex Mol. Cell. Biol. 21 2001 281 288
39. M. de Jager, J. van Noort, D.C. van Gent, C. Dekker, and R. Kanaar Human Rad50/Mre11 is a flexible complex that can tether DNA ends Mol. Cell 8 2001 1129 1135
40. M. van den Bosch, R.T. Bree, and N.F. Lowndes The MRN complex: coordinating and mediating the response to broken chromosomes EMBO Rep. 4 2003 844 849
41. J. Bartkova, J. Tommiska, L. Oplustilova, K. Aaltonen, and A. Tamminen Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene Mol. Oncol. 2 2008 296 316
42. S. Angele, I. Treilleux, A. Bremond, P. Taniere, and J. Hall Altered expression of DNA double-strand break detection and repair proteins in breast carcinomas Histopathology 43 2003 347 353
43. K. Soderlund, O. Stal, L. Skoog, L.E. Rutqvist, and B. Nordenskjold Intact Mre11/Rad50/Nbs1 complex predicts good response to radiotherapy in early breast cancer Int. J. Radiat. Oncol. Biol. Phys. 68 2007 50 58
44. Kalev, P. and Sablina, A.A. (2011) Protein phosphatase 2A as a potential target for anticancer therapy. Anti-cancer Agents Med. Chem. 11, 38-46.
45. S. Moreau, J.R. Ferguson, and L.S. Symington The nuclease activity of Mre11 is required for meiosis but not for mating type switching, end joining, or telomere maintenance Mol. Cell. Biol. 19 1999 556 566
46. Allen, C., Ashley, A.K., Hromas, R. and Nickoloff, J.A. (2011) More forks on the road to replication stress recovery. J. Mol. Cell. Biol. 3, 4-12.
47. H. Lodish, A. Berk, P. Matsudaira, C.A. Kaiser, and M. Krieger Molecular Biology of the Cell 2004 WH Freeman New York
48. M.A. de la Torre-Ruiz, C.M. Green, and N.F. Lowndes RAD9 and RAD24 define two additive, interacting branches of the DNA damage checkpoint pathway in budding yeast normally required for Rad53 modification and activation EMBO J. 17 1998 2687 2698
49. D. D'Amours, and S.P. Jackson The yeast Xrs2 complex functions in S phase checkpoint regulation Genes Dev. 15 2001 2238 2249